Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration

BACKGROUND: Bevacizumab (Bev), a monoclonal antibody to vascular endothelial growth factor (VEGF), is used in combination with chemotherapy for the treatment of metastatic colorectal cancer (CRC). The effects of Bev on angiogenesis have been well described, but the direct effect of Bev on tumour cel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Fan, F, Samuel, S, Gaur, P, Lu, J, Dallas, N A, Xia, L, Bose, D, Ramachandran, V, Ellis, L M
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2011
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3078594/
https://ncbi.nlm.nih.gov/pubmed/21407219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.81
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados